Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment

The connection between glutathione status and immune resilience was powerfully demonstrated in this landmark randomized controlled trial by De Flora, Grassi, and Carati, published in the European Respiratory Journal.

The researchers enrolled 262 elderly subjects (a population particularly vulnerable to influenza) and randomized them to receive either N-acetylcysteine (NAC) at 600 mg twice daily or placebo for 6 months during flu season. NAC is the most well-established oral precursor to glutathione, raising intracellular GSH levels by providing the rate-limiting amino acid cysteine.

The results were striking. While NAC did not prevent influenza infection itself (seroconversion rates were similar between groups), it dramatically attenuated clinical disease. Among subjects who became infected, only 25% of those on NAC developed symptomatic illness compared to 79% on placebo. The severity and duration of symptoms were also significantly reduced. Simultaneously, cell-mediated immunity shifted progressively from anergy (immune non-responsiveness) toward normal function.

This study demonstrates that maintaining adequate glutathione levels — even indirectly through precursor supplementation — can profoundly influence how the immune system handles infections. Rather than preventing exposure, optimal GSH status enables the immune system to mount an effective yet controlled response that resolves infections with minimal symptoms.